摘要
目的探讨不同剂量聚乙二醇洛塞那肽治疗糖尿病肾病(DKD)的疗效并分析其对肾功能指标的差异性影响。方法选取2020年1月至2021年1月在本院收治的97例DKD患者的临床资料,去除1例随机未用药者,最终纳入96例患者。按不同聚乙二醇洛塞那肽给药剂量分为100μg组、200μg组、300μg组,每组各32例。对三组患者的临床疗效进行评价,对治疗前后三组患者的空腹血糖(FBG)、糖化血红蛋白(HbA1c)、血清肌酐(Scr)、尿素氮(BUN)、胱抑素C(CysC)和血清β2微球蛋白(β2-MG)水平以及24 h尿微量蛋白定量进行测定并比较。观察三组患者的不良事件和不良反应发生率。结果100μg组患者的治疗总有效率低于200μg组和300μg组(59.38%vs.75.00%vs.93.75%,均P<0.05)。与治疗前比较,三组患者治疗后的FBG、HbA1c、Scr、BUN、CysC、β2-MG、24h尿微量蛋白定量水平逐渐降低,差异均统计学意义(均P<0.05)。三组的不良事件和不良反应发生率逐渐升高,差异均有统计学意义(均P<0.05)。结论聚乙二醇洛塞那肽可有效改善DKD患者的肾脏功能,具有临床推广使用价值,但仍需要注意其剂量依赖性不良反应发生率。
Objective To investigate the efficacy of different doses of pegylated loxenatide in the treatment of diabetic kidney disease(DKD)and analyze its differential effects on renal function parameters.Methods The clinical data of 97 patients with DKD admitted to our hospital from January 2020 to January 2021 were selected.One patient who was randomly unmedicated was removed and 96 patients were finally included.They were divided into 100μg group,200μg group and 300μg group according to different doses of polyethylene glycol loxenatide,with 32 cases in each group.The clinical efficacy of the three groups was evaluated,and the fasting blood glucose(FBG),glycosylated hemoglobin(HbAlc),serum creatinine(Scr),blood urea nitrogen(BUN),cystatin C(Cys C)and serumβ2 microglobulin(β2-MG)levels and 24 h urinary microprotein quantification were measured in the three groups before and after treatment.The incidence of adverse events and adverse reactions was observed in the three groups.Results The ORR in 100μg group was lower than that in 200μg group and 300μg group(59.38%vs.75.00%vs.93.75%,all P<0.05).After treatment,the quantitative levels of FBG,HbAlc,Scr,BUN,Cys C,β2-MG,and 24 h urinary microprotein in the three groups gradually decreased,and the differences were statistically significant(all P<0.05).The incidence of adverse events and adverse reactions in the three groups gradually increased,and the differences were statistically significant(all P<0.05).Conclusions Polyethylene glycol losenatide can effectively improve the kidney function of DKD patients,and has the value of clinical promotion,but the incidence of dose-dependent adverse reactions still needs attention.
作者
袁晓岚
汪琳姣
席巍
杨小华
Yuan Xiaolan;Wang Linjiao;Xi Wei;Yang Xiaohua(Department of Endocrinology,Hai'an People's Hospital,Hai'an 226600,China)
出处
《国际泌尿系统杂志》
2023年第5期870-873,共4页
International Journal of Urology and Nephrology
关键词
糖尿病肾病
聚乙二醇洛塞那肽
肾功能
Diabetic Nephropathies
Polyethylene Glycol Loxenatide
Kidney Function
作者简介
通信作者:杨小华,Email:80298151@qq.com。
